Veterinary & Companion Animal
Helping pets live longer,
and the practices that care for them.
Golden Lotus Labs brings the same pharmaceutical-grade standards we apply in human medicine to companion-animal care — including CoA-documented BPC-157 for licensed veterinary practices exploring research-use protocols in recovery, mobility, and healing.
Get Partner Portal Access →
The Research
What the science actually shows.
BPC-157 is a synthetic peptide derived from a protective protein found in gastric juice. It was first studied for gastrointestinal healing, and research interest has since expanded into tissue and tendon repair pathways relevant to recovery and mobility care.
Direct clinical trial evidence in dogs and cats remains limited — most mechanistic research comes from preclinical models. The most concrete data point available today is a canine repeated-dose safety and tolerability study, which found BPC-157 well tolerated at studied doses. Golden Lotus Labs presents this as investigational, research-use material for licensed veterinary professionals, not as an approved treatment with guaranteed outcomes.
Market Momentum
A fast-growing category in veterinary care.
Integrative and rehab-focused veterinary practices are increasingly fielding questions about peptide-based recovery support, driven by rising consumer awareness and demand for non-surgical options in joint, mobility, and post-injury care. Practices that can speak knowledgeably to companion-animal peptide options — and source them from a documented, CoA-backed supplier — are positioned to meet that demand as it continues to grow.
Research Library
Curated public research on companion-animal peptides.
PubMed
Preclinical safety evaluation of body protective compound-157
A repeated-dose toxicity study in dogs found BPC-157 well tolerated, with no meaningful abnormalities versus control except a creatinine dip at the highest dose tested.
View Study →PMC (National Library of Medicine)
Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
Found BPC-157 dose- and time-dependently increased growth hormone receptor expression in tendon fibroblasts, one proposed mechanism behind its tendon-healing effects in preclinical models.
View Study →Partner Portal Access
Tell us about your practice.
No licensing paperwork required to get started — just tell us a bit about your practice and our team will follow up to set up your partner portal access.